Navigation Links
Biotech Begins Year on a Quiet, but Optimistic Note
Date:2/2/2011

SAN FRANCISCO, Feb. 2, 2011 /PRNewswire/ -- The biotech industry opened the New Year quietly with the Burrill Biotech Select Index up marginally for January at 0.3 percent. Meanwhile, the capital markets recorded their strongest January in years. The Dow Jones Industrial average closed the month with a 2.7 percent gain and the Nasdaq Composite index closed up 1.8 percent.

"Although not yet reflected in biotech's performance on the capital markets, the mood at the annual J.P. Morgan Healthcare Conference in San Francisco early January was upbeat reflecting the fact that many biotech and pharma CEOs believe that 2011 will be a good one for them," said G. Steven Burrill, CEO, Burrill & Company, a diversified global financial services firm focused on the life sciences industry.

"I believe we will see an increase in M&A activity in biotech land as companies position themselves for growth this year. It was clear that pharma executives were checking out promising companies to bolster their product pipelines...and several large biotechs, sitting on plenty of cash, made their intentions known that they are looking to acquire assets. Amgen, for example, pulled the trigger on a $1 billion deal late January to acquire BioVex, the creator of a late-stage cancer vaccine that has shown encouraging results in treating solid tumors," noted Burrill.

"We will also see in the next couple of weeks a final resolution to Sanofi Aventis' bid to acquire Genzyme," commented Burrill. "In addition, at the J.P. Morgan event several big pharma companies re-emphasized the growing importance of emerging markets to strengthen their bottom line," added Burrill. "It has been well documented that the global pharmaceutical market is poised to grow by as much as 7 percent this year and emerging markets will be a big part of that growth as more government spending and broader access to health care in developing economies drive demand."

The Burrill Personalized Index climbed almost 3 percent in January. "As we describe in our upcoming 25th anniversary issue of our annual report Biotech 2011, this sector will be hot," commented Burrill. "There is no doubt that we are moving to a world that embraces not only the possibility of using a person's genetic information to identify their risks for disease but also individualized strategies for prevention or treatment and companies in the healthcare sector are positioning themselves for this trend. As a result, we are seeing plenty of deals as companies orient their R&D strategies in the personalized medicine space."

Market Cap

According to the January issue of the Burrill Report, (www.burrillreport.com) the biotech industry's collective market cap was $378 billion, up 1.5 percent for the month.


'/>"/>
SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. ThirdBiotech Announces Kemeta as Newest Sponsor
4. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
5. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
8. China Kangtai Cactus Biotech Announces Record Second Quarter Results
9. Yongye Biotechnology International Announces Second Quarter Results
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):